Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis

Fig. 4

Combinated effects of raltitrexed and anlotinib on cell invasion in ESCC cells. A and C After treatment with control, 20 μM anlotinib, 2.5 μM raltitrexed or 20 μM anlotinib + 2.5 μM raltitrexed for 24 h, invaded cells were stained and counted using microscopy in KYSE-30 (A) and TE-1 (C) cells. B and D Quantitative analysis of the number of invaded cells in KYSE-30 (B) and TE-1 (D) cells. Data indicate means + SD of three biological replicates. Student’s t test; ***P < 0.001 (versus control); ##P < 0.01, ###P < 0.001 (versus 20 μM anlotinib or 2.5 μM raltitrexed)

Back to article page